• Johnson & Johnson launched the Dual Energy THERMOCOOL SMARTTOUCH SF Platform in Europe, broadening its cardiac ablation portfolio in a fast-growing atrial fibrillation market.
• The system positions the group with a differentiated dual-energy offering, strengthening competitiveness as rivals push newer ablation modalities across Europe.
• Launch leverages an established installed base and workflow familiarity, supporting faster adoption and pull-through for the company’s broader electrophysiology ecosystem.
• Clinical data cited 86.9% effectiveness at 12 months in a first-in-human study subgroup, supporting commercialization and physician confidence.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.